


status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone metabolism, or for accelerating bone growth or repair, which composition is characterized by the inclusion of a peptide (SEQ ID NO: 7).

3. (Once Amended) The pharmaceutical composition according to Claim 1, wherein the peptide (SEQ ID NO: 6) is



5. (Once Amended) A method of preparing a pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, which method comprises the mixing of a peptide according to the sequence (SEQ ID NO: 6).

7. (Once Amended) The method of Claim 5, wherein the peptide is
- pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

8. (Once Amended) A method of treatment of an individual suffering from osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, or at risk of so suffering, which comprises the administration to said individual of a therapeutically effective amount of a pharmaceutical composition which includes a peptide according to the sequence (SEQ ID NO: 7).

10. (Once Amended) The method of Claim 8, wherein the peptide is (SEQ ID NO: 6)
- pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

11. (Once Amended) A new use for a peptide according to the sequence (SEQ ID NO: 7)



or a salt thereof

wherein **Xaa¹** is His or Tyr,
Xaa² is Trp or Leu, and
Xaa³ is Tyr or Arg,

Provided that when **Xaa¹** is Tyr and **Xaa²** is Leu, then **Xaa³** is not Arg, which use is as a therapeutic agent for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone growth.

12. (Once Amended) A new use for a peptide according to the sequence (SEQ ID NO: 6)
pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

which use is as a therapeutic agent for the treatment of osteoporosis and other disorders of bone growth.

REMARKS

Applicants submit this Amendment to indicate the insertion point for the substitute Sequence Listing filed concurrently herewith. Applicants respectfully request examination on the merits of this application.

Receipt of the initial Office Action on the merits is awaited.

Respectfully submitted,

23 November 2001
Date


Stephen A. Bent
Reg. No. 29,768

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5300
Facsimile: (202) 672-5399